HALEOS LABS
NSE: HALEOSLABS · ISIN INE320X01016 · Healthcare
₹1,420.00+19.60 (+1.40%)
Monday 9 November, 10:16 IST. Delayed. Source: Yahoo Finance.
Price chart
This chart is unavailable right now.
The day
- Previous close
- ₹1,400.40
- Open
- ₹1,390.00
- Day high
- ₹1,425.00
- Day low
- ₹1,390.00
Listed on NSE since 17 August 2017.
Key numbers
- Market value
- ₹422.90 Cr
- P/E (trailing)
- 26.76
- EPS (trailing)
- ₹52.27
- Price to book
- 1.98
- Dividend yield
- 0.11%
- Debt to equity
- 0.48
- Profit margin
- 4.9%
- Beta
- 0.35
- Volume today
- 165
- Average volume
- 997
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹312.55 Cr | ₹11.46 Cr |
| FY24 | ₹299.56 Cr | ₹9.09 Cr |
| FY25 | ₹336.78 Cr | ₹20.11 Cr |
| FY26 | ₹315.53 Cr | ₹17.31 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | ₹73 Cr | ₹3 Cr | −36.3% |
| Q4 FY26Jan–Mar 2026Audited | ₹75 Cr | ₹43.57 L | −85.3% |
| Q3 FY26Oct–Dec 2025 | ₹95 Cr | ₹7 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹81 Cr | ₹6 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹83 Cr | ₹4 Cr | – |
| Q4 FY25Jan–Mar 2025Audited | ₹89 Cr | ₹3 Cr | – |
Source: HALEOS LABS’s results filed with NSE, consolidated (the whole group). Net profit is the share of HALEOS LABS’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | March 2026 | September 2025 |
|---|---|---|
| Fixed assets | ₹277 Cr | ₹235 Cr |
| Investments | ₹3.61 L | ₹0 |
| Inventories | ₹80 Cr | ₹71 Cr |
| Owed by customers | ₹61 Cr | ₹61 Cr |
| Cash and equivalents | ₹1 Cr | ₹53.92 L |
| Total assets | ₹454 Cr | ₹394 Cr |
| Borrowings | ₹109 Cr | ₹68 Cr |
| Total liabilities | ₹225 Cr | ₹171 Cr |
| Shareholders’ equity | ₹214 Cr | ₹206 Cr |
Source: HALEOS LABS’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About HALEOS LABS
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also export its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
- Industry
- Biotechnology
- Based in
- Hyderabad
- Employees
- 611
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name HALEOS LABS in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 1.50 Per Share
Dividend · ex-date 23 September 2026
- Dividend - Rs 1.50 Per Share
Dividend · ex-date 24 September 2025
- Annual General Meeting/Dividend - Rs 1.50 Per Share
Dividend · ex-date 23 September 2024
- Annual General Meeting/Dividend - Rs 1.50 Per Share
Dividend · ex-date 22 September 2023
- Annual General Meeting/Dividend - Rs 1.50 Per Share
Dividend · ex-date 22 September 2022
- Annual General Meeting/Dividend - Rs 1.50 Per Share
Dividend · ex-date 20 September 2021
- Dividend - Rs 1.50 Per Share
Dividend · ex-date 19 September 2019
- Annual General Meeting
Action · ex-date 12 September 2018
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.